Specialty drug market access reality check
Specialty drug market access reality check
Insight

Specialty drug market access reality check

Ten payer pressures to act on now

Specialty drug manufacturers face a mountain of information and misinformation on payer tactics in the evolving healthcare environment. Differentiating between what’s real and what’s hype is a difficult task.

The newest thought leadership from KPMG helps pharmaceutical companies focus on developments that require them to “Act Now,” those that allow for a “Watch and Wait” stance, and those they can “Deprioritize,” at least for now. Readers should come away with a clear idea of how to modify their strategies related to evidence generation, marketing and pricing & market access to meet payer priorities and ensure favorable reimbursement outcomes.

Specialty drug market access reality check

Ten payer pressures to act on now.